Hong Kong Stock Development Pharmaceuticals plummeted 67%
Hong Kong Stock Development Pharmaceuticals plummeted 67%.
The company announced that the interim phase III analysis of the oral COVID-19 drug proclamide was not statistically significant and will seek to revise the clinical trial plan.
$KINTOR PHARMA-B (09939.HK)$
The company announced that the interim phase III analysis of the oral COVID-19 drug proclamide was not statistically significant and will seek to revise the clinical trial plan.
$KINTOR PHARMA-B (09939.HK)$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Twitter@Sino_Market | Realtime Chinese market info provider.
9473Followers
4Following
8961Visitors
Follow